ArticleObesity surgery2018
Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery.
Article in Obesity surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2019Pooled it
- Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians.Journal of family medicine and primary care · 2024Article
- Antiretroviral Therapy during Long-term Surgical Care: 'Exploring Difficult Cases in HIV Clinics' of the Korean Society for AIDS Conference in 2023.Infection & chemotherapy · 2024Review
- Impact of Bariatric Surgery in the Short and Long Term: A Need for Time-Dependent Dosing of Drugs.Obesity surgery · 2023Review
- Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients.Infection & chemotherapy · 2022Review
- Antiretroviral Therapy Efficacy Post-Bariatric Weight Loss Surgery: A Case Series of Persons Living with Human Immunodeficiency Virus.Obesity surgery · 2022Article
- Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.Clinical pharmacokinetics · 2022Review
- Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.Current obesity reports · 2021Review
- Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders.Antimicrobial agents and chemotherapy · 2021Article
- NASH in HIV.Current HIV/AIDS reports · 2020Review
- HIV and antiretroviral therapy-related fat alterations.Nature reviews. Disease primers · 2020Review
- Review
- Medication management and pharmacokinetic changes after bariatric surgery.Canadian family physician Medecin de famille canadien · 2020Review
- Obesity and Weight Gain in Persons with HIV.Current HIV/AIDS reports · 2020 · on this mapReview
- Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.Antimicrobial agents and chemotherapy · 2020Article
- Increased Paracetamol Bioavailability after Sleeve Gastrectomy: A Crossover Pre- vs. Post-Operative Clinical Trial.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAnti-retroviral therapy (ART) dramatically reduced AIDS development, thus enabling patients to live as long as the general population. New challenges have emerged particularly cardiometabolic diseases and weight gain, with some HIV patients seeking bariatric surgery (BS). However, BS outcomes during HIV remain poorly described, with scarce data on ART pharmacokinetic post-BS.
objectiveDescribing sleeve gastrectomy (SG) results in HIV patients in terms of ART pharmacokinetic, HIV control, weight loss, and metabolic outcomes. DESIGN, SETTING, AND PATIENTS: Prospective study of HIV patients undergoing SG in a referral academic center, with at least 6 months follow-up.
main outcome measureClinical and biological parameters, HIV medical history, and ART pharmacokinetics were gathered before and post-SG.
resultsSeventeen patients (mean BMI = 44.2 ± 5.7 kg m
conclusionsSG seems effective and safe in obese HIV patients. However, ART treatment should be monitored post-SG to control HIV infection. We suggest that some ART should be adapted before SG conjoints with infectious disease specialists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.